Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapoxetine Withdrawal Effects in Premature Ejaculation
NCT00210613Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Nov 2004
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of dapoxetine in premature ejaculation (PE), sponsored by Johnson & Johnson. Started Nov 2004; status: completed.
02
Drugs
dapoxetine
03
Conditions
premature ejaculation (PE)
Beyond the preview
Go deeper on NCT00210613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00210613.